Boosting protection for patients with non-acute cardiovascular disease: a focus on antithrombotic regimen (a consensus expert opinion from the Egyptian Society of Cardiology working group of thrombosis and prevention).
Ahmed BendaryBassem ZarifHala Mahfouz BadranKhaled ShokryHamza KabilPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)
For some stable atherosclerotic CVD patients who are at high risk of cardiovascular events and at low risk for bleeding, a regimen of rivaroxaban and aspirin might be taken into consideration.
Keyphrases
- cardiovascular events
- cardiovascular disease
- atrial fibrillation
- end stage renal disease
- coronary artery disease
- pulmonary embolism
- chronic kidney disease
- ejection fraction
- newly diagnosed
- low dose
- clinical practice
- peritoneal dialysis
- prognostic factors
- liver failure
- type diabetes
- acute kidney injury
- cardiovascular risk factors
- patient reported outcomes
- hepatitis b virus
- intensive care unit
- percutaneous coronary intervention
- aortic dissection
- drug induced
- patient reported